Zobrazeno 1 - 10
of 86
pro vyhledávání: '"Leucèmia mieloide"'
Autor:
Lucía Pérez-Lamas, Alejandro Luna, Concepción Boque, Blanca Xicoy, Pilar Giraldo, Raúl Pérez López, Concepción Ruiz Nuño, Natalia De las Heras, Elvira Mora Casterá, Javier López Marín, Adrián Segura Díaz, Valle Gómez, Patricia Vélez Tenza, Magdalena Sierra Pacho, Juan Antonio Vera Goñi, Melania Moreno Vega, Alberto Alvarez-Larrán, Montse Cortés, Manuel Pérez Encinas, Patricia Carrascosa Mastell, Anna Angona, Ana Rosell, Sunil Lakhwani, Mercedes Colorado, Elena Ramila, Carlos Cervero, Beatriz Cuevas, Lucía Villalón Blanco, Raquel de Paz, Antonio Paz Coll, María José Fernández, Luis Felipe Casado, Juan Manuel Alonso-Domínguez, María Magdalena Anguita Arance, Araceli Salamanca Cuenca, Antonio Jiménez-Velasco, Santiago Osorio Prendes, Marta Santaliestra, María José Lis Chulvi, Juan Carlos Hernández-Boluda, Valentín García-Gutiérrez
Publikováno v:
Scientia
Cancers
Volume 15
Issue 4
Pages: 1045
Cancers
Volume 15
Issue 4
Pages: 1045
Simple Summary After the recent irruption of asciminib into the therapeutic arsenal for chronic myeloid leukemia, real-life data remain scarce to determine which patients may benefit most from this drug. Data on the efficacy of the drug in real-world
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::95d62a6253d555f83c73979b06dacbda
https://hdl.handle.net/11351/9705
https://hdl.handle.net/11351/9705
Autor:
Luca Vinci, Christian Flotho, Peter Noellke, Dirk Lebrecht, Riccardo Masetti, Valerie de Haas, Barbara De Moerloose, Michael Dworzak, Henrik Hasle, Tayfun Güngör, Jan Starý, Dominik Turkiewicz, Marek Ussowicz, Cristina Diaz de Heredia, Jochen Buechner, Kirsi Jahnukainen, Krisztian Kallay, Ivana Bodova, Owen P. Smith, Marco Zecca, Dorine Bresters, Peter Lang, Tania Nicole Masmas, Roland Meisel, Herbert Pichler, Miriam Erlacher, Gudrun Göhring, Franco Locatelli, Brigitte Strahm, Charlotte M. Niemeyer, Ayami Yoshimi
Publikováno v:
Scientia
Vinci, L, Flotho, C, Noellke, P, Lebrecht, D, Masetti, R, de Haas, V, De Moerloose, B, Dworzak, M, Hasle, H, Güngör, T, Starý, J, Turkiewicz, D, Ussowicz, M, de Heredia, C D, Buechner, J, Jahnukainen, K, Kallay, K, Bodova, I, Smith, O P, Zecca, M, Bresters, D, Lang, P, Masmas, T N, Meisel, R, Pichler, H, Erlacher, M, Göhring, G, Locatelli, F, Strahm, B, Niemeyer, C M & Yoshimi, A 2023, ' Second allogeneic stem cell transplantation can rescue a significant proportion of patients with JMML relapsing after first allograft ', Bone Marrow Transplantation, vol. 58, no. 5, pp. 607-609 . https://doi.org/10.1038/s41409-023-01942-4
Vinci, L, Flotho, C, Noellke, P, Lebrecht, D, Masetti, R, de Haas, V, De Moerloose, B, Dworzak, M, Hasle, H, Güngör, T, Starý, J, Turkiewicz, D, Ussowicz, M, de Heredia, C D, Buechner, J, Jahnukainen, K, Kallay, K, Bodova, I, Smith, O P, Zecca, M, Bresters, D, Lang, P, Masmas, T N, Meisel, R, Pichler, H, Erlacher, M, Göhring, G, Locatelli, F, Strahm, B, Niemeyer, C M & Yoshimi, A 2023, ' Second allogeneic stem cell transplantation can rescue a significant proportion of patients with JMML relapsing after first allograft ', Bone Marrow Transplantation, vol. 58, no. 5, pp. 607-609 . https://doi.org/10.1038/s41409-023-01942-4
Myeloproliferative disease; Paediatrics Enfermedad mieloproliferativa; Pediatría Malaltia mieloproliferativa; Pediatria Open Access funding enabled and organized by Projekt DEAL.
Autor:
Lionel Adès, Larisa Girshova, Vadim A. Doronin, María Díez-Campelo, David Valcárcel, Suman Kambhampati, Nora-Athina Viniou, Dariusz Woszczyk, Raquel De Paz Arias, Argiris Symeonidis, Achilles Anagnostopoulos, Eduardo Ciliao Munhoz, Uwe Platzbecker, Valeria Santini, Robert J. Fram, Ying Yuan, Sharon Friedlander, Douglas V. Faller, Mikkael A. Sekeres
Publikováno v:
Scientia
Pevonedistat; Chronic myelomonocytic leukemia Pevonedistat; Leucemia mielomonocítica crónica Pevonedistat; Leucèmia mielomonocítica crònica PANTHER is a global, randomized phase 3 trial of pevonedistat+azacitidine (n = 227) vs azacitidine monoth
Autor:
Xavier Calvo, David Roman-Bravo, Nieves Garcia-Gisbert, Juan Jose Rodriguez-Sevilla, Sara Garcia-Avila, Lourdes Florensa, Joan Gibert, Concepción Fernández-Rodríguez, Marta Salido, Anna Puiggros, Blanca Espinet, Luis Colomo, Beatriz Bellosillo, Ana Ferrer, Leonor Arenillas
Publikováno v:
Blood Advances. 6:3921-3931
Patients with oligomonocytic chronic myelomonocytic leukemia (OM-CMML) are currently classified according to the 2017 World Health Organization myelodysplastic syndromes classification. However, recent data support considering OM-CMML as a specific s
Autor:
Núñez Amela, Yáiza
[cat] La leucèmia mieloide aguda (LMA) és un grup heterogeni de malalties hematològiques que s'originen a partir de la proliferació clonal excessiva de cèl·lules precursores mieloides. Actualment, malgrat que la majoria de pacients inicialment
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od_______963::46e3bebca850a3e39ddc11d31143117b
http://hdl.handle.net/2445/197605
http://hdl.handle.net/2445/197605
Autor:
Michael Boyiadzis, Pinkal Desai, Nikki Daskalakis, William Donnellan, Lucille Ferrante, Jenna D. Goldberg, Michael R. Grunwald, Christina Guttke, Xiang Li, Jose Antonio Perez‐Simon, Olga Salamero, Trevor Tucker, Xiaoying Xu, Jay Yang, Naveen Pemmaraju, Juan Manuel Alonso‐Dominguez
Publikováno v:
Scientia
Targeting antibody; Acute myeloid leukemia Anticòs dirigit; Leucèmia mieloide aguda Anticuerpo dirigido; Leucemia mieloide aguda This study aimed to identify a recommended phase II dose and evaluate the safety, tolerability, pharmacokinetics/pharma
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::20b8698a543f8b70c1edbf809b973f8a
https://hdl.handle.net/11351/9400
https://hdl.handle.net/11351/9400
Autor:
Marin-Bejar, Oskar, Romero Moya, Damià, Rodríguez Ubreva, Javier, Distefano, Maximiliano, Lessi, Francesca, Aretini, Paolo, Liquori, Alessandro, Castaño, Julio, Kozyra, Emilia, Kotmayer, Lili, Bueno, Clara, Cervera, José, Rodriguez-Gallego, José Carlos, Nomdedéu Guinot, Josep Francesc, Murillo-Sanjuán, Laura, Díaz de Heredia, Cristina, Pérez-Martínez, Antonio, López-Cardenas, Félix, Martínez-Laperche, Carolina, Dorado-Herrero, Nieves, Marco, Francisco M., Prósper, Felipe, Menendez, Pablo, Valcárcel, David, Ballestar Tarín, Esteban, Bödör, Csaba, Bigas Salvans, Anna, Català, Albert, Wlodarski, Marcin W, Giorgetti, Alessandra
GATA2 deficiency is a complex multi-system disorder with high risk of developing myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) with a nearly complete lifetime penetrance1, 2. GATA2 carriers show a highly variable expressivity, with
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od_______963::caf26be8128f4e4abe974cd98e0ac4e5
http://hdl.handle.net/2445/193572
http://hdl.handle.net/2445/193572
Autor:
Natalia Estrada, Lurdes Zamora, Francisca Ferrer-Marín, Laura Palomo, Olga García, Patricia Vélez, Iris De la Fuente, Miguel Sagüés, Marta Cabezón, Montserrat Cortés, Rolando Omar Vallansot, María Alicia Senín-Magán, Concepción Boqué, Blanca Xicoy
Publikováno v:
Scientia
Journal of Clinical Medicine; Volume 11; Issue 20; Pages: 6217
Journal of Clinical Medicine; Volume 11; Issue 20; Pages: 6217
Chronic myeloid leukemia; Imatinib; Single-nucleotide polymorphisms Leucèmia mieloide crònica; Imatinib; Polimorfismes d'un sol nucleòtid Leucemia mieloide crónica; Imatinib; Polimorfismos de un sólo nucleótido Imatinib is the most common first
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4df9b0a89f39aecaece2124d53b508dd
http://hdl.handle.net/11351/8974
http://hdl.handle.net/11351/8974
Autor:
Stéphane de Botton, Pau Montesinos, Andre C. Schuh, Cristina Papayannidis, Paresh Vyas, Andrew H. Wei, Hans Ommen, Sergey Semochkin, Hee-Je Kim, Richard A. Larson, Jaime Koprivnikar, Olga Frankfurt, Felicitas Thol, Jörg Chromik, Jenny Byrne, Arnaud Pigneux, Xavier Thomas, Olga Salamero, Maria Belen Vidriales, Vadim Doronin, Hartmut Döhner, Amir T. Fathi, Eric Laille, Xin Yu, Maroof Hasan, Patricia Martin-Regueira, Courtney D. DiNardo
Publikováno v:
Scientia
Enasidenib; Conventional care Enasidenib; Atenció convencional Enasidenib; Atención convencional This open-label, randomized, phase 3 trial (NCT02577406) compared enasidenib, an oral IDH2 (isocitrate dehydrogenase 2) inhibitor, with conventional ca
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3715a5d50e378580e2588f9f261b90de
https://ora.ox.ac.uk/objects/uuid:f5d7e243-e3f5-4a9c-b91e-69a2fc98cc60
https://ora.ox.ac.uk/objects/uuid:f5d7e243-e3f5-4a9c-b91e-69a2fc98cc60
Autor:
Vilorio-Marqués, Laura, Castañón Fernández, Christelle, Mora, Elvira, Gutiérrez, Lorena, Rey Bua, Beatriz, Jiménez Lorenzo, Maria José, Díaz-Beyá, Marina, Vara Pampliega, Miriam, Molero, Antonieta, Sánchez-García, Joaquín, Calabuig, Marisa, Cedena, María Teresa, Chen-Liang, Tzu, Díaz Santa, Johana Alejandra, Padilla, Irene, Hernández, Francisca, Díez, Rosana, Asensi, Pedro, Xicoy, Blanca, Sanz, Guillermo, Valcárcel, David, Diez-Campelo, María, Bernal, Teresa, Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras, Universitat Autònoma de Barcelona
Publikováno v:
Scientia
WOS:000863670500001
Therapeutic Advances in Hematology
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname
r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
WOS:000863670500001
Therapeutic Advances in Hematology
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname
r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
The authors declared the following potential conflict of interest with respect to the research, authorship, and/or publication of this article: T.B. has received support for attending meetings and/or travel from Jazz Pharmaceutical, honoraria from Ja
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b3d71fb600d405ad30c8a84cd0deda3f
https://hdl.handle.net/10668/20232
https://hdl.handle.net/10668/20232